Man stretching in park

Preserving Patient Freedom With PD

Our peritoneal dialysis (PD) products and services can help people with kidney disease to maintain their chosen lifestyle. We were the first to make this therapy broadly available to patients,1 and we continue to drive it forward with a range of dialysis solutions and automated PD systems with digital connectivity. Our Sharesource for PD allows clinicians to review treatment data remotely and take timely action.

Improving access to PD therapy and raising the quality of care

Since pioneering peritoneal dialysis in 1960, we have been committed to providing patients with chronic kidney disease (CKD) with this lifesaving therapy. This treatment option enables patients undergoing peritoneal dialysis at home to maintain their lifestyle and independence while offering potentially better clinical outcomes and substantially lower costs — benefiting patients, providers and healthcare systems alike.2

Through its partnership with the nephrology community, Vantive is committed to improving access to PD therapy and raising the quality of care to help achieve better outcomes for patients. Today, we offer the market’s most comprehensive PD portfolio, including the first and most thoroughly studied renal RPM platform. We believe in the value PD brings and are focused on making it the preferred initial choice of dialysis therapy through smarter patient-first solutions.

Man reading a book while receiving treatment

Benefits of PD therapy

Life goals

Most PD patients are more satisfied with their treatment compared to hemodialysis (HD) patients3,4

Shared decision-making

Shared decision-making supports patient satisfaction and leads to an increase in patients choosing PD.5

Early survival

PD offers significant early survival benefits vs ICHD6

Preservation of RFK

PD allows a better preservation of Residual Kidney Function (RKF) than HD for patients starting dialysis, and this is associated with better patient survival7,8

Bridge to transplant

PD is associated with favorable post-transplant outcomes9

Preservation of vascular access

Initiating dialysis with PD preserves vascular access and eliminates the risk of HD access infections and complications8

Reduced infections and hospitalization rates

Evidence-based preventative strategies have significantly improved peritonitis rates over the past decade10,11

Patient candidacy

At least 78% of patients have no absolute medical or psychosocial contraindication for PD12

Addressing health disparities

Opportunity exists to increase the use of PD among all appropriate patient groups, regardless of their background13

Multiple therapy options

The PD therapy options that Vantive offers include continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD).

Patient receives CAPD therapy in their home
Man sleeping at home next to treatment machine
CAPD therapy (manual exchange)

CAPD has several benefits in comparison to other types of dialysis. Waste products and excess fluid can be removed manually during the treatment process, which may reduce stress on a patient's body. While doing CAPD, patients may be able to eat more of the foods they enjoy and take fewer medications than if they were doing hemodialysis (HD).14

APD therapy

APD automates the delivery of dialysis solution to the patient, along with removing the excess fluid and waste. This therapy may provide increased flexibility with a patient's diet and the number of medications a patient needs to take while on dialysis.14

Vantive’s comprehensive PD portfolio includes Homechoice Claria and voice-guided Amia APD Systems, both enabled by the Sharesource.

Learn more about the  Amia APD System and  Homechoice Claria APD System.

Benefits of remote patient management (RPM)

Remote patient management — in which patients’ clinical data is digitally collected and transmitted to their hospital or clinic for monitoring and analysis — has been shown to have trends indicating fewer hospitalizations, reduce patient drop-out, increase time on therapy, provide improved access to care and lower utilization of healthcare resources.15-20

*Image does not depict real patient data.

Learn about Sharesource remote patient management
Woman on laptop viewing Sharesource remote patient management
Learn about Sharesource remote patient management

Evidence supporting RPM21-24

Besides offering clinicians and patients innovations that enhance the PD experience and a comprehensive PD portfolio including APD cyclers powered by RPM, Vantive provides intuitive educational resources designed to increase clinicians’ and patients’ confidence in using PD.

Read more
Woman preparing treatment for son in bedroom
Read more
Healthcare professional sitting at table on phone

Renal care resources to support clinicians

We offer a wealth of resources that provide detailed information on using our APD systems, our Sharesource remote patient management platform and our support services for both clinicians and patients.

View resources

My Kidney Journey

The My Kidney Journey website is an essential online resource that offers patients a variety of educational tools and resources to support making informed choices about dialysis options.

Visit my Kidney Journey website
A woman looks at her mobile device in a well-lit living room
Visit my Kidney Journey website

Important Safety Information

For the safe and proper use of the products mentioned herein, please refer to the appropriate Instructions for Use or the appropriate Operator's Manual.

Intended Use: The Amia Automated PD System is intended for automatic control of dialysate solution exchanges in the treatment of adult renal failure patients undergoing peritoneal dialysis. All therapies using the Amia Automated PD System must be prescribed and performed under the responsibility of a physician who is familiar and well-informed about peritoneal dialysis.

------------------------------------

Intended Use: Homechoice Claria APD system is intended for automatic control of dialysis solution exchanges in the treatment of pediatric and adult renal failure patients undergoing peritoneal dialysis in the home healthcare environment including comparable use in professional healthcare facilities.

------------------------------------

Intended Use: The Sharesource portal is intended for use by healthcare professionals to remotely communicate with compatible dialysis instruments and transfer data to a central database to aid in the review, analysis, and evaluation of patients’ historical treatment results. This system is not intended to be a substitute for good clinical management practices nor does its operation create decisions or treatment pathways.

------------------------------------

Indication: DIANEAL Peritoneal dialysis solutions are indicated for patients in acute or chronic renal failure when nondialytic medical therapy is judged to be inadequate. It may also be indicated in the treatment of certain fluid and electrolyte disturbances, and for patients intoxicated with certain poisons and drugs. However, for many substances other methods of detoxification have been reported to be more effective than peritoneal dialysis.

Intended Use: DIANEAL is intended for intraperitoneal administration only. Not for intravenous administration.

Please click here to view Vantive product labeling information for:

  • Contraindications in patients with hypersensitivity reactions due to corn starch allergy; severe lactic acidosis or have a condition known to increase the risk of lactic acidosis; uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase the risk of infection; documented loss of peritoneal function or extensive adhesions.
  • Most serious warnings and precautions regarding risk of anaphylactic/anaphylactoid reactions; severe lactic acidosis; encapsulating peritoneal sclerosis and fatal outcomes due to this condition.
  • Other relevant warning and precautions: Hypersensitivity reactions, peritonitis, congestive heart failure, volume depletion, or shock.
  • Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

------------------------------------

Indication: EXTRANEAL (icodextrin, sodium chloride, sodium lactate, calcium chloride, magnesium chloride) is indicated for use as an osmotic agent for long dwell, up to 12 hours, in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD), where it can be used for 14 and up to 16 hours.

Intended Use: EXTRANEAL is intended for intraperitoneal administration only. Not for intravenous administration.

Please click here to view Vantive product labeling information for:

  • Contraindications in patients with acute renal failure; allergy to corn starch and/or icodextrin; maltose or isomaltose intolerance; glycogen storage disease; pre-existing severe lactic acidosis; uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase the risk of infection; documented loss of peritoneal function or extensive adhesions.
  • Most serious warnings and precautions regarding risk of serious hypersensitivity reactions such as toxic epidermal necrolysis, angioedema, serum sickness, erythema multiforme and vasculitis; anaphylactic/anaphylactoid reactions; severe lactic acidosis; false hyperglycemia reading with some types of glucose monitors or test strips.
  • Other relevant warning and precautions: Hypersensitivity reactions, eosinophilia, peritonitis, congestive heart failure, volume depletion, or shock.
  • Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

Vantive, Amia, Dianeal, Extraneal, Homechoice, Homechoice Claria and Sharesource are trademarks of Vantive Health LLC or its affiliates.

References

  1. Guest S. Handbook of Peritoneal Dialysis. CreateSpace Independent Publishing Platform; 2010:9.

  2. François K, Bargman JM. Evaluating the benefits of home-based peritoneal dialysis. Int J Nephrol Renovasc Dis. 2014;7:447-455.

  3. Lee SW, Lee NR, Son SK, et al. Comparative study of peritoneal dialysis versus hemodialysis on the clinical outcomes in Korea: a population-based approach. Sci Rep. 2019;9(1):5905.

  4. Zazzeroni L, Pasquinelli G, Nanni E, Cremonini V, Rubbi I. Comparison of quality of life in patients undergoing hemodialysis and peritoneal dialysis: a systematic review and meta-analysis. Kidney Blood Press Res. 2017;42(4): 717-727.

  5. Devoe DJ, Wong B, James MT, et al. Patient education and peritoneal dialysis modality selection: a systematic review and meta-analysis. Am J Kidney Dis. 2016;68(3):422-433.

  6. Marshall MR. The benefit of early survival on PD versus HD—why this is (still) very important. Perit Dial Int. 2020;40(4):405-418.

  7. Bargman JM, et al. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12(10):2158-2162.

  8. Almasri JM, et al. Outcomes of vascular access for hemodialysis: a systematic review and meta-analysis. J Vasc Surg. 2016;64(1):236-243.

  9. Joachim E, et al. Association of pre-transplant dialysis modality and post-transplant outcomes: a meta-analysis. Perit Dial Int. 2017;37(3):259-265.

  10. Marshall MR, et al. A systematic review of peritoneal dialysis-related peritonitis rates over time from national or regional population-based registries and databases. Perit Dial Int. 2022;42(1):39-47.

  11. United States Renal Data System. 2021 USRDS Annual Data Report: Epidemiology of kidney disease in the United States: End Stage Renal Disease: Chapter 5. Hospitalization. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

  12. Mendelssohn DC, et al. A prospective evaluation of renal replacement therapy modality eligibility. Nephrol Dial Transplant. 2009;24(2):555-561

  13. United States Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of kidney disease in the United States: End Stage Renal Disease: Chapter 1. Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. National Institute of Diabetes and Digestive and Kidney Diseases.

  14. National Kidney Foundation. Peritoneal dialysis. 2024. Accessed September 20, 2024. https://www.kidney.org/kidney-topics/peritoneal-dialysis.

  15. Firanek C, Knowles MA, Sloand JA. The impact of automated peritoneal dialysis (APD) with remote patient management (RPM): changing the nursing paradigm to proactive clinical management (SP508). Poster presented at: 54th ERA-EDTA Congress; June 3-6, 2017; Madrid, Spain.

  16. Firanek C, Salas M, Gellens M, Gatesman RD, Wiebenson D, Sloand J. Discrepancy between prescripted and actual APD prescription delivery: identification using cycler remote management technology (MP-557). Poster presented at: 54th ERA-EDTA Congress; June 3-6, 2017; Madrid, Spain.

  17. Makhija D, Alscher MD, Becker S, et al. Remote monitoring of automated peritoneal dialysis patients: assessing clinical and economic value. Telemed J E Health. 2018;24(4):315-323.

  18. Rivera AS, Sanabria M, Vesga J, Suarez AM, Bunch A. Comparison of hospitalization rate in automatized PD patients with and without remote management program in Colombia. J Am Soc Nephrol. 2018;29:595-596.

  19. Corzo L, Vesga J, Sanabria M, Rivera A. Clinical outcomes in remote patient monitoring in automated peritoneal dialysis: a Colombian experience. Nephrol Dial Transplant. 2020;35(suppl 3):gfaa142.P1151.

  20. Sanabria M, Vesga J, Lindholm B, Rivera A, Rutherford P. Time on therapy of automated peritoneal dialysis with and without remote patient monitoring: a cohort study. Int J Nephrol. 2022;2022:8646775.

  21. Firanek C, Salas M, Gellens M, Gatesman RD, Wiebenson D, Sloand J. Discrepancy between prescribed and actual APD prescription delivery: Identification using cycler remote management technology. Neph Dial Trans. 2017;32(suppl 3):iii633.

  22. Sanabria M, Buitrago G, Lindholm B, et al. Remote patient monitoring program in automated peritoneal dialysis: impact on hospitalizations. Perit Dial Int. 2019;39(5):472-478. 

  23. Wood E, McCarthy K, Roper M. Remote monitoring of peritoneal dialysis: evaluating the impact of the Claria Sharesource system. J Kidney Care. 2019;4(1):16-24.

  24. Firanek C, Knowles M, Sloand J. Impact of remote patient management in hospitals conducting APD: shifting the nursing care paradigm. Neph Dial Trans. 2017;32(suppl 3): iii300.